At Bader Sultan’s Genetic & Metabolic Division, we stand at the forefront of rare disease innovation, dedicated to transforming the lives of patients with genetic and metabolic disorders across Kuwait and beyond.
Through trusted partnerships with leading global biopharma companies, we bring cutting-edge therapies and advanced diagnostic solutions that offer new hope where few options exist. Our mission is to ensure timely access to life-saving treatments and deliver the highest standard of care, while empowering healthcare professionals with the latest knowledge and support. Driven by compassion, science, and excellence, our division continues to redefine what’s possible in rare disease management, one patient, one family, and one success story at a time.
- Brineura (cerliponase alfa) for CLN2 disease.
- Vimizim (elosulfase alfa) for Morquio A Syndrome MPS IVA.
- Kuvan (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution for PKU.
- Naglazyme (galsulfase) for MPS VI.
- Firdapse (amifampridine phosphate) (currently approved in the EU only) for LEMS.
- Orfadin (nitisinone) treatment for tyrosinemia type 1.
- Kineret® (anakinra) treatment for Neonatal onset multisystem inflammatory disease.
- Alprolix Eftrenonacog alfa treatment for hemophilia B.
- Elocta® efmoroctocog alfa treatment for hemophilia A.
- Aldurazyme(laronidase) treatment for MPS type I.
- Myozyme(alglucosidase alfa) treatment for pompe disease.
- Cerezyme(imiglucerase) treatment for Gaucher disease.
- Cerdelga (eliglustat) treatment for adult Gaucher disease.
- Carbaglu (carglumic acid) treatment of acute hyperammonemia.
- Cosmegen (Dactinomycin) treatment regimen for metastatic, nonseminomatous testicular cancer.
- Cystadane (betaine anhydrous for oral solution) treatment of homocystinuria.
- Cystadrops (Cysteamin) treatment of corneal cystine crystal deposits.
- Cystagon (Cysteamine bitartrate) treatment of nephropathic cystinosis.
- Normosang (human hemin) treatment of acute attacks of hepatic porphyria.
- Pedea (ibuprofen)Treatment of a haemodynamically significant patent ductus arteriosus.
- Vedrop (tocofersolan) vitamin E deficiency.
- Wilzin (zinc acetate dehydrate) Treatment of Wilson's disease.
- Ammonul® (sodium phenylacetate and sodium benzoate treatment for acutehyperammonemia.
- Ammonaps® (sodium phenylbutyrate) treatment for chronic hyperammonemia.
- Ravicti (Glycerol phenylacetate) treatment for Chronic hyperammonemia.
